Document:

Document

SOLO BRANDS, INC. 
2021 INCENTIVE AWARD PLAN

PERFORMANCE STOCK UNIT GRANT NOTICE

Capitalized terms not specifically defined in this Performance Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2021 Incentive Award Plan (as amended from time to time, the “Plan”) of Solo Brands, Inc. (the “Company”).

The Company has granted to the participant listed below (“Participant”) the Awards that vest subject to Performance Criteria described in this Grant Notice (the “Performance Stock Units” or “PSUs”), subject to the terms and conditions of the Plan and the Performance Stock Unit Agreement attached as Exhibit A (the “Agreement”), both of which are incorporated into this Grant Notice by reference.						
		
	Participant:	
	Grant Date:	
	Number of PSUs:	
	Vesting Schedule:

	Subject to the Participant’s continuous service through the applicable vesting date, the PSUs shall become 100% vested if the Company achieves _______ at the conclusion of a fiscal quarter that begins at any time during the two-year period immediately following the Grant Date (such two-year period, the “Vesting Term”). If the _______ Target is achieved with respect to any such fiscal quarter that begins during the Vesting Term, the PSUs shall be deemed vested as of the date that the Company’s quarterly _____________ is publicly-reported for such fiscal quarter.

For purposes of this Agreement, __________ means the Company’s publicly-reported quarterly _________ as of the conclusion of the applicable fiscal quarter.

The PSUs will be automatically forfeited by the Participant without payment of any consideration therefor if the ________ Target is not achieved in a fiscal quarter that begins at any time during the Vesting Term.

If the Participant’s continuous service terminates, all PSUs that have not become vested on or prior to the date of such termination will thereupon be automatically forfeited by the Participant without payment of any consideration therefor.

		

By Participant’s signature below, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement.  Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement.  Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement.															
					
	SOLO BRANDS, INC.		PARTICIPANT
	

By:
			
	Name:
	John Merris		[Participant Name]	
	Title:
	CEO			

PERFORMANCE STOCK UNIT AGREEMENT

Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan.

ARTICLE I.
GENERAL

1.1    Award of PSUs.  The Company has granted the PSUs to Participant effective as of the grant date set forth in the Grant Notice (the “Grant Date”).  Each PSU represents the right to receive one Share or, at the option of the Company, an amount of cash, in either case, as set forth in this Agreement.  Participant will have no right to the distribution of any Shares or payment of any cash until the time (if ever) the PSUs have vested.

1.2    Incorporation of Terms of Plan.  The PSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference.  In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.

1.3    Unsecured Promise.  The PSUs will at all times prior to settlement represent an unsecured Company obligation payable only from the Company’s general assets.

ARTICLE II.
VESTING; FORFEITURE AND SETTLEMENT

2.1    Vesting; Forfeiture.  The PSUs will vest according to the vesting schedule in the Grant Notice except that any fraction of a PSU that would otherwise be vested will be accumulated and will vest only when a whole PSU has accumulated.  In the event of Participant’s Termination of Service for any reason, all unvested PSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company, including the Grant Notice.  

2.2    Settlement
.
         (a)    PSUs will be settled in Shares or cash at the Company’s option as soon as administratively practicable after the vesting of the applicable PSU, but in no event more than thirty (30) days after the PSU’s vesting date.  Notwithstanding the foregoing, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Law until the earliest date the Company reasonably determines the making of the payment will not cause such a violation (in accordance with Treasury Regulation Section 1.409A-2(b)(7)(ii)), provided the Company reasonably believes the delay will not result in the imposition of excise taxes under Section 409A.

             (b)    At the time of settlement, Participant will receive one Share for each vested PSU.  No fractional Shares will be issued upon settlement. The Company, in its sole discretion, may instead substitute an amount in cash for the vested PSU.  If a PSU is settled in cash, the amount of cash paid with respect to the PSU will equal the Fair Market Value of a Share on the day immediately preceding the settlement date.  

ARTICLE III. 
TAXATION AND TAX WITHHOLDING

3.1    Representation.  Participant represents to the Company that Participant has reviewed with Participant’s own tax advisors the tax consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement.  Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.

3.2    Tax Withholding.

             (a)     Participant will not receive any shares issued upon settlement of the vested PSUs unless Participant makes arrangements acceptable to the Company to pay any withholding taxes that may be due as a result of the settlement of the vested PSUs.  The Company has the right and option, but not the obligation, to treat Participant’s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the PSUs as Participant’s election to satisfy all or any portion of the withholding tax by requesting the Company reduce the amount of such withholding taxes from other compensation payable to the Participant or retain Shares otherwise issuable under the Award. The Company shall not be obligated to deliver any certificate representing Shares issuable with respect to the PSUs to, or to cause any such Shares to be held in book-entry form by, Participant or his or her legal representative unless and until Participant or his or her legal representative shall have paid or otherwise satisfied in full the amount of all federal, state, local and foreign taxes applicable with respect to the taxable income of Participant resulting from the vesting and settlement of the PSUs or any other taxable event related thereto.

            (b)    Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the PSUs, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the PSUs.  Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the PSUs or the subsequent sale of Shares.  The Company and the Subsidiaries do not commit and are under no obligation to structure the PSUs to reduce or eliminate Participant’s tax liability.

3.3    Broker-Assisted Sales.  In the event any tax withholding obligation arising in connection with the PSUs will be satisfied under Section 9.5(c) of the Plan, then the Company may elect to instruct any broker acceptable to the Company for such purpose to sell on Participant’s behalf a whole number of Shares from those Shares then issuable upon the settlement of the PSUs as the Company determines to be appropriate to generate cash proceeds sufficient to satisfy the tax withholding obligation and to remit the proceeds of such sale to the Company or Subsidiary thereof with respect to which the withholding obligation arises.  Participant’s acceptance of these PSUs constitutes Participant’s instruction and authorization to the Company and such broker to complete the transactions described in this Section 3.3, including the transactions described in the previous sentence, as applicable.  In the event of any broker-assisted sale of Shares in connection with the payment of tax withholdings: (a) any Shares to be sold through a broker-assisted sale will be sold on the day the tax withholding obligation occurs or arises, or as soon thereafter as reasonably practicable; (b) such Shares may be sold as part of a block trade with other participants in the Plan in which all participants receive an average price; (c) Participant will be responsible for all broker’s fees and other costs of sale, and Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale; (d) to the extent the proceeds of such sale exceed the applicable tax withholding obligation, the Company agrees to pay such excess in cash to Participant as soon as reasonably practicable; (e) Participant acknowledges that the Company or its designee is under no obligation to arrange for such sale at any particular price, and that the proceeds of any such sale may not be sufficient to satisfy the applicable tax withholding obligation; and (f) in the event the proceeds of such sale are insufficient to satisfy the applicable tax 

withholding obligation, Participant agrees to pay immediately upon demand to the Company or its applicable Subsidiary with respect to which the withholding obligation arises an amount in cash sufficient to satisfy any remaining portion of the applicable withholding obligation.

ARTICLE IV.
OTHER PROVISIONS

4.1    Administration.  The Administrator shall have the power to interpret the Plan, the Grant Notice and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan, the Grant Notice and this Agreement as are consistent therewith and to interpret, amend or revoke any such rules.  All actions taken and all interpretations and determinations made by the Administrator will be final and binding upon Participant, the Company and all other interested persons.  To the extent allowable pursuant to Applicable Law, no member of the Committee or the Board will be personally liable for any action, determination or interpretation made with respect to the Plan, the Grant Notice or this Agreement.

4.2    PSUs Not Transferrable.  Unless otherwise determined by the Administrator, (a) the PSUs may not be sold, assigned or transferred, pledged or otherwise encumbered, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, subject to the Administrator’s consent, pursuant to a domestic relations order and (b) neither the PSUs nor any interest or right therein or part thereof shall be liable for the debts, contracts or engagements of Participant or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy).  Any attempted disposition thereof shall be null and void and of no effect, except to the extent that such disposition is permitted by this Section 4.2. 

4.3    Adjustments.  Upon the occurrence of certain events as provided in Article VIII of the Plan, Participant acknowledges that the PSUs and the Shares subject to the PSUs are subject to adjustment, modification and termination.

4.4    Notices.  Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company’s Secretary at the Company’s principal office or the Secretary’s then-current email address or facsimile number.  Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant’s last known mailing address, email address or facsimile number in the Company’s personnel files.  By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party.  Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation.

4.5    Titles.  Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.

4.6    Governing Law.  The PSUs, Grant Notice and this Agreement will be governed by and interpreted in accordance with the laws of the State of Delaware, disregarding any state’s choice-of-law principles requiring the application of a jurisdiction’s laws other than the State of Delaware.

4.7    Conformity to Securities Laws.  Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws.

4.8    Successors and Assigns.  The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer set forth in the Plan and this Agreement, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.

4.9    Limitations Applicable to Section 16 Persons.  Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement, the PSUs will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3) that are requirements for the application of such exemptive rule.  To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule.

4.10    Section 409A.  The PSUs are not intended to constitute “nonqualified deferred compensation” within the meaning of Section 409A.  However, notwithstanding any other provision of the Plan, the Grant Notice or this Agreement, if at any time the Administrator determines that the PSUs (or any portion thereof) may be subject to Section 409A, the Administrator shall have the right in its sole discretion (without any obligation to do so or to indemnify Participant or any other person for failure to do so) to adopt such amendments to the Plan, the Grant Notice or this Agreement, or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Administrator determines are necessary or appropriate for the PSUs either to be exempt from the application of Section 409A or to comply with the requirements of Section 409A. 

4.11    Claw-back Provisions.  The PSUs (including any proceeds, gains or other economic benefit the Participant actually or constructively receives upon receipt of the PSUs or the settlement or resale of any Shares underlying this PSUs) will be subject to any Company claw-back policy as in effect from time to time, including any claw-back policy adopted to comply with Applicable Laws (including the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder). 

4.12    Entire Agreement.  The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof.

4.13    Agreement Severable.  In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement.

4.14    Limitation on Participant’s Rights.  Participation in the Plan confers no rights or interests other than as herein provided.  This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust.  Neither the Plan nor any underlying program, in and of itself, has any assets.  Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the PSUs, and rights no greater than the right to receive cash or the Shares as a general unsecured creditor with respect to the PSUs, as and when settled pursuant to the terms of this Agreement.

4.15    No Rights as Stockholder.  Neither Participant nor any person claiming under or through Participant will have any of the rights or privileges of a stockholder of the Company in respect of any Shares issuable upon settlement of the PSUs unless and until certificates representing such Shares (which may be in book-entry form) will have been issued and recorded on the records of the Company or its transfer agents or registrars and delivered to Participant (including through electronic delivery to a 

brokerage account). No adjustment will be made for a dividend or other right for which the record date is prior to the date of such issuance, recordation and delivery, except as provided in Article VIII of the Plan. 

4.16    Not a Contract of Employment.  Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant.

4.17    Counterparts.  The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument.  Delivery of an executed counterpart of a signature page to this Agreement by facsimile, “.pdf” format, scanned pages or other electronic means shall be effective as delivery of a manually executed counterpart to this Agreement.

* * * * *EX-10.1

 Exhibit 10.1 

August 10, 2022 
 Vincerx Pharma, Inc. 

260 Sheridan Avenue, Suite #400 
 Palo Alto, California 94306 

Attn: Ahmed Hamdy, M.D. 
 Dr. Hamdy: 

This letter (“Agreement”) confirms our understanding that Vincerx Pharma, Inc., (the “Company”) has engaged LifeSci Consulting, LLC
(“LifeSci”), to act as its non-exclusive advisor with respect to the Company’s effort to secure strategic collaboration or licensing transactions (each a “Transaction”) with strategic
partners (each a “Strategic Partner”) for the products or technologies (the “Assets”) listed on Exhibit A. LifeSci shall coordinate with the Company before making contact with any third party in connection with potential
Transactions. 
 1. As part of our engagement, LifeSci will, if appropriate and if requested by the Company: 

 

	 	(a)	 familiarize ourself with the research and development, product pipeline, operations, finances, business and
strategy of the Company and potential Strategic Partners; 

  

	 	(b)	 assist the Company in identifying and evaluating potential Strategic Partners and use commercially reasonable
efforts to secure one or more Transactions for the Assets with Strategic Partners; 

  

	 	(c)	 assist the Company in preparing informational materials describing the Company’s Assets for delivery to
prospective Strategic Partners, which materials shall be based upon information supplied to LifeSci by the Company and approved by the Company, and assist the Company in coordinating the data room and the due diligence activities of potential
Strategic Partners; 

  

	 	(d)	 introduce prospective Strategic Partners to the Company and facilitate interactions; 

 

	 	(e)	 provide periodic progress reports to the Company detailing market contact activity and interactions with
Strategic Partners; 

  

	 	(f)	 assist the Company in a valuation analysis of the Assets and transaction comparables analyses to support
negotiating one or more Transactions; 

  

	 	(g)	 assist the Company in negotiating with Strategic Partners, including structuring and negotiating the non-binding and binding agreements associated with a Transaction, and closing Transactions with Strategic Partners; 

  
 1 

	 	(h)	 at all times liaise with the Company and maintain open communication with the Company’s designated
representatives; and 

  

	 	(i)	 be available to meet with the Company’s Board of Directors to discuss any proposed Transaction and its
implications. 

 2. In connection with LifeSci’s engagement, the Company will furnish LifeSci with all information
concerning the Company and, to the extent available to the Company, the Assets, which LifeSci and the Company reasonably deem appropriate, and will provide LifeSci with access to the officers, directors, employees, accountants, counsel and other
representatives (collectively, the “Representatives”) of the Company and, as practicable, the Assets, it being understood that LifeSci will rely solely upon such information supplied by the Company and its Representatives without assuming
any responsibility for independent investigation or verification thereof. In addition, the Company agrees to promptly advise LifeSci of any material event or change in the business, affairs, condition (financial or otherwise) or prospects of the
Company or, to the knowledge of the Company, the Assets that occurs during the term of LifeSci’s engagement hereunder and is relevant to a potential Transaction. All non-public information concerning the
Company or the Assets which is given to LifeSci will be used solely in the course, and for the purpose, of the performance of our services hereunder and will be treated confidentially by us for so long as it remains
non-public. Except as otherwise required by applicable law or judicial or regulatory process, LifeSci will not disclose this information to a third party without the Company’s prior written consent. 

3. As compensation for our services hereunder, the Company agrees to pay LifeSci non-refundable
payments as follows: 
  

	 	(a)	 A monthly retainer (the “Retainer Fee”) equal to ten thousand dollars ($10,000) for each month in the
Term. The first Retainer Fee will become due within five (5) business days of executing this Agreement and the Company’s receipt of LifeSci’s invoice and each subsequent Retainer Fee will become due thirty (30) days following the
Company’s receipt of LifeSci’s invoice, issued on or about each monthly anniversary of date first written above. The aggregate Retainer Fee paid by the Company shall be fully creditable against any Success Fee. 

 

	 	(b)	 A success fee (the “Success Fee”) equal to three percent (3%) of the Total Cash Amount actually
received by the Company or any of its subsidiary entities in connection with a Transaction (the “Transaction Proceeds”) that is consummated with a Strategic Partner during the Term or the Trailer Period (as defined below) and with respect
to which the Company has requested that LifeSci provide, and LifeSci has provided, the services provided for in this Agreement. The Success Fee will become due within five (5) business days of the Company’s receipt of the Transaction
Proceeds. The “Total Cash Amount” shall mean the total amount of cash 

  
 2 

	 	
received by the Company or any of its subsidiary entities at or in connection with the closing of a Transaction and any future cash milestone payments in connection with the Transaction (but not
royalties or any other contingent or future payments) received by the Company or any of its subsidiary entities within three years of the closing of the Transaction (the “Success Fee Window”). By way of clarity, the Total Cash Amount shall
not include any amounts paid or payable to the Company or its subsidiary entities for (i) the purchase of equity or debt securities or options, warrants or other rights to acquire such equity or debt securities, (ii) the purchase of goods
or services, (iii) loans or advances, (iv) rights or licenses attributable to products or technology other than the Assets, or (v) reimbursement for services or other activities, including personnel costs and out-of-pocket costs payable to third parties (including, without limitation, costs for prosecuting, maintaining or enforcing any intellectual property rights).

 The portion of a Success Fee that is attributable to any escrow release or applicable milestone payment received during the
Success Fee Window shall be paid to LifeSci only when and if such payments are received by the Company or its subsidiary entities. No Success Fee shall be payable with respect to payments received by the Company or its subsidiary entities after the
expiration of the Success Fee Window. In the event that a Success Fee to LifeSci would be owed for a Transaction and a success fee to a third party would also be owed for the same Transaction, the Company and LifeSci agree to negotiate in good faith
regarding an appropriate allocation between the parties entitled to a success fee for such Transaction that (i) takes into account the relative contributions of such parties to the identification and successful completion of such Transaction
and the relative amount each party would have been entitled to receive in connection with such Transaction, and (ii) avoids a situation where the Company is required to pay more than one success fee for the same Transaction. 

A minimum success fee (the “Minimum Success Fee”) equal to two hundred fifty thousand dollars ($250,000) will apply to all
Transactions. The Company shall have the sole right in its discretion to accept or reject any offer received from a prospective Strategic Partner. 

4. In addition, the Company agrees to periodically reimburse LifeSci (but not more frequently than monthly) for all reasonable out-of-pocket expenses, including travel expenses (the “Travel Costs”) and the reasonable fees and expenses (the “Other Expenses”), if any, of any third
party retained by LifeSci, and approved by the Company, to act on behalf of the Company, resulting from or arising out of this engagement. Travel Costs and Other Expenses will not be incurred without the Company’s prior written approval, will
comply with Company’s then-applicable travel and expense policy and will not include any expenses associated with negotiating this Agreement. 

  
 3 

 5. For purposes of this Agreement, a Transaction shall include, without limitation, any
licensing agreements, distribution agreements, option agreements for a license or collaboration arrangement, partnerships, joint ventures, research collaborations, or any other collaborations that generate economic benefit to the Company. A
Transaction shall not include (i) a transaction or series of related transactions that involve a sale or other transfer for value of all or a majority of the equity, business or assets of the Company, whether in the form of a merger,
consolidation, tender or exchange offer, stock purchase, asset purchase or other acquisition in which the shares of capital stock held by the stockholders of the Company immediately prior to such acquisition continue to represent, or are converted
into or exchanged for shares of capital stock that represent, immediately after such acquisition and by virtue of the acquisition, less than a majority of the total outstanding voting power of the surviving or acquiring person or entity; or
(ii) a bona fide debt or equity financing. 
 6. The term (the “Term”) of this engagement shall be for twelve
(12) months from the date of this Agreement. In the event of expiration or termination (other than termination by the Company for cause prior to expiration of the Agreement), the Company shall pay to LifeSci any and all fees and expenses
provided for herein with respect to any Transaction which is consummated during the six (6) month period (“Trailer Period”) after such expiration or termination, so long as such Transaction is consummated with a Strategic Partner with
respect to which (i) the Company requested that LifeSci provide, and LifeSci provided, the services provided for in this Agreement up to such expiration or termination, and (ii) the Company, during the Term, (A) entered into a
confidentiality agreement and (B) exchanged a substantive term sheet or entered into a feasibility study, research evaluation study, material transfer agreement or other similar type of agreement for the purpose of evaluating the Assets prior
to executing a Transaction. The Company has the right to terminate this Agreement without cause upon ten (10) days written notice following completion of the fourth (4th) month of the Term
(“Termination Option”). If the Company exercises the Termination Option, the Company shall no longer be obligated to pay to LifeSci the monthly retainer associated with the months of this engagement following the effective date of the
termination. 
 7. The Company acknowledges that LifeSci may, at its option and expense and after public announcement of a Transaction,
place announcements and advertisements or otherwise publicize the Transaction and LifeSci’s role in it (which may include the reproduction of the Company’s logo and a hyperlink to the Company’s website) on LifeSci’s website and
in other newspapers and journals as it may choose, stating that LifeSci has acted as advisor to the Company in connection with the Transaction, and in such event, the Company agrees to make available to LifeSci the Company’s company logo for
such use. LifeSci shall submit an initial copy of any such announcement, advertisement or publication to the Company for its review, comment and approval (such approval not to be unreasonably withheld). Furthermore, if requested by LifeSci, the
Company shall include a mutually acceptable reference to LifeSci in any press release or other public announcement made by the Company regarding the matters described in this Agreement. 

8. Information (including any copies thereof), except for that portion of the Information which consists of market analyses, compilations,
studies or other documents prepared by LifeSci, or its agents, representatives or employees and which do not pertain specifically to the Company or the Assets, will be returned to the Company immediately upon

  
 4 

 
the Company’s request. That portion of the Information which consists of market analyses, compilations, written studies or other documents, including the confidential business review,
prepared by LifeSci or its agents, representatives or employees and which do not pertain specifically to the Company or the Assets, will be retained by LifeSci, but will be shared with the Company but not any third parties. As used herein, the term
Information shall include all data, reports, records, business opportunities and general information pertaining to the Company disclosed to LifeSci by or through the Company. 

9. The parties have entered into a Bilateral Confidentiality Agreement effective as of June 9, 2022 (the “CDA”), which governs
the disclosure and use of Confidential Information (as defined in the CDA) and which shall remain in full force and effect during and after the Term in accordance with its terms, provided that this Agreement and the terms, conditions and rates
contained herein may be disclosed by the parties to the extent required by applicable law or regulation or the rules of any stock exchange 

10. The failure of either party to insist, in any one or more instances, upon performance of the terms or conditions of this Agreement shall
not be construed as a waiver or relinquishment of any right granted hereunder or of the future performance of any such term or condition. 

11. Each party shall indemnify, defend and hold harmless the other party and the other party’s directors, officers, employees, agents and
affiliates (the “Indemnitees”) from and against any and all third-party damages, expenses, penalties, fines, costs, fees (including reasonable attorney’s fees) and liabilities (collectively, “Losses”) incurred in connection
with the indemnifying party’s action or inaction under this Agreement, except to the extent such Losses are attributable to a material breach of this Agreement or the gross negligence or intentional misconduct of the Indemnitees. 

12. This Agreement and the CDA constitute the complete understanding between the parties with respect to the arrangement contemplated herein.
No modification or waiver of any provision of this engagement shall be valid unless in writing and signed by both parties. 
 13. LifeSci
may not, without the Company’s prior written consent, subcontract or otherwise delegate or assign this Agreement or any of its obligations under this Agreement, whether by operation of law or otherwise. Any attempted delegation, subcontracting
or assignment by LifeSci without Company’s consent shall be null and void. The Company may, without LifeSci’s consent, assign all or any part of this Agreement to an affiliate or in connection with the sale of substantially all of its
business or assets (whether by merger, sale of stock or assets, reorganization or any similar transaction). 
 14. This Agreement shall be
governed by the laws of the State of New York and the competent courts of the State of New York shall have exclusive jurisdiction over any disputes arising hereunder. 

15. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which shall constitute
together the same instrument. The Parties to this Agreement agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The Parties agree they
will have no rights to challenge the use or authenticity of this document based solely on the absence of an original signature. 

  
 5 

 LifeSci is delighted to accept this engagement and looks forward to working with the Company on this
assignment. Please confirm that the foregoing is in accordance with your understanding by signing and returning to us the enclosed duplicate of this Agreement. 

 

			
	 Very truly yours,

	
	 LIFESCI CONSULTING, LLC

		
	 By:
	 	 /s/ Michael Casey Cozart

	 Name: Michael Casey Cozart

	 Title: Managing Partner

 Accepted and agreed to as of the date first written above: 

 

			
	 VINCERX PHARMA, INC.

		
	 By:
	 	 /s/ Ahmed Hamdy

	 Name: Ahmed Hamdy, MD

	 Title: CEO

  
 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]